Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00456053 | A Randomized Study of the Safety and Efficacy of FG-2216 in Subjects With Renal Anemia Not Requiring Dialysis and Not Receiving Recombinant Human Erythropoietin | PHASE2 | COMPLETED | 145 | — | — | Dec 1, 2005 | Jul 1, 2007 | Nov 6, 2007 | 27 | United States |
| Name | Type | Description |
|---|---|---|
| FG2216 | DRUG | - |
Inclusion Criteria: * Stage 3 or 4 chronic kidney disease * appropriate hemoglobin levels Exclusion Criteria: * Neovascular age related macular degeneration requiring treatment * Macular edema or proliferative retinopathy in diabetic subjects, requiring treatment * Any history of malignancy * The...